- Home
- TLSI vs CIK Comparison
TLSI vs CIK Comparison
Compare TLSI & CIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- CIK
- Stock Information
- Founded
- TLSI 2010
- CIK 1987
- Country
- TLSI United States
- CIK United States
- Employees
- TLSI N/A
- CIK N/A
- Industry
- TLSI Medical Specialities
- CIK Finance/Investors Services
- Sector
- TLSI Health Care
- CIK Finance
- Exchange
- TLSI Nasdaq
- CIK Nasdaq
- Market Cap
- TLSI 160.4M
- CIK 156.6M
- IPO Year
- TLSI N/A
- CIK N/A
- Fundamental
- Price
- TLSI $5.02
- CIK $2.83
- Analyst Decision
- TLSI Strong Buy
- CIK
- Analyst Count
- TLSI 6
- CIK 0
- Target Price
- TLSI $11.75
- CIK N/A
- AVG Volume (30 Days)
- TLSI 34.6K
- CIK 115.4K
- Earning Date
- TLSI 05-23-2025
- CIK 01-01-0001
- Dividend Yield
- TLSI N/A
- CIK 9.03%
- EPS Growth
- TLSI N/A
- CIK N/A
- EPS
- TLSI N/A
- CIK N/A
- Revenue
- TLSI $29,431,000.00
- CIK N/A
- Revenue This Year
- TLSI $55.13
- CIK N/A
- Revenue Next Year
- TLSI $50.71
- CIK N/A
- P/E Ratio
- TLSI N/A
- CIK N/A
- Revenue Growth
- TLSI 58.99
- CIK N/A
- 52 Week Low
- TLSI $3.50
- CIK $2.50
- 52 Week High
- TLSI $10.24
- CIK $3.19
- Technical
- Relative Strength Index (RSI)
- TLSI 34.87
- CIK 53.58
- Support Level
- TLSI $4.66
- CIK $2.81
- Resistance Level
- TLSI $5.40
- CIK $2.83
- Average True Range (ATR)
- TLSI 0.37
- CIK 0.03
- MACD
- TLSI -0.06
- CIK 0.01
- Stochastic Oscillator
- TLSI 29.51
- CIK 83.33
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About CIK Credit Suisse Asset Management Income Fund Inc.
Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. Credit Suisse serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations, and individuals.